Related Experiment Video
Updated: Mar 12, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
20.2K
Metformin: From Research to Clinical Practice
Meng H Tan1, Hussain Alquraini1, Kara Mizokami-Stout1
1Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Endocrinology and Metabolism Clinics of North America
|November 9, 2016
Summary
Metformin is a safe, first-line oral medication for type 2 diabetes that lowers blood sugar by reducing liver glucose production. It offers benefits including weight neutrality, reduced microvascular complications, and lower cardiovascular mortality.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) is a global health challenge requiring effective glucose-lowering strategies.
- Hyperglycemia management is crucial for preventing T2DM complications.
- Metformin is the established first-line oral antihyperglycemic agent.
Purpose of the Study:
- To summarize the pharmacological actions and clinical benefits of metformin.
- To highlight metformin's role in managing T2DM and other related conditions.
Main Methods:
- Review of existing pharmacological data and clinical trial outcomes.
- Analysis of metformin's mechanism of action and safety profile.
- Evaluation of metformin's efficacy in various patient populations.
Main Results:
- Metformin primarily reduces hepatic gluconeogenesis, improving glycemic control.
- It is weight-neutral or associated with weight loss, unlike some other antidiabetic agents.
- Metformin use is linked to reduced risks of microvascular complications and cardiovascular mortality compared to sulfonylureas.
Conclusions:
- Metformin is a cornerstone therapy for T2DM due to its efficacy, safety, and favorable metabolic profile.
- Its applications extend beyond T2DM to include gestational diabetes, polycystic ovary syndrome, and prediabetes prevention.
- Metformin represents a cost-effective and well-tolerated option for managing hyperglycemia.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
793
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
793
01:16Clinical Trials
11.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
11.0K
01:06Oral Hypoglycemic Agents: Glinides
804
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
804
01:11Clinical Trials: Overview
5.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K